NervGen Pharma Corp. to Present at the 9th Annual LD Micro Invitational

LOS ANGELES, CA / ACCESSWIRE / June 4, 2019 / NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a regenerative medicine company dedicated to creating innovative solutions for the treatment of nerve damage, including spinal cord and peripheral nerve injury, today announced that it will be presenting at the 9th annual LD Micro Invitational on Wednesday, June 5 at 8:40AM PDT / 11:40AM EDT. Ernest Wong, NervGen’s President & CEO, will be presenting and meeting with investors.

“This year’s Invitational will showcase some of the most unique names in the financial world, from early-stage start-ups to well-established names on the national exchanges,” stated Chris Lahiji, LD Micro’s President. “Even though LD has emerged as one of the largest and most influential organizations in the space, our focus has never deviated from showcasing some of the more interesting businesses in the world to our ever growing community.”

The LD Micro Invitational will take place June 4th and 5th in Los Angeles, at the Luxe Sunset Bel Air Hotel, will feature 230 companies, and will be attended by over 1,000 individuals.

View NervGen’s profile here: http://www.ldmicro.com/profile/NGENF

Profiles powered by LD Micro – News Compliments of Accesswire

About NervGen

NervGen is restoring life’s potential by creating innovative solutions for the treatment of nerve damage, including spinal cord injuries and peripheral nerve injuries. The Company also continues to research secondary applications such as multiple sclerosis, stroke, acute myocardial infarction induced arrhythmia (“AMI”, commonly known as a heart attack) and other neurodegenerative diseases.

NervGen plans to initiate a Phase 1 human clinical trial for its lead compound, NVG-291, in early 2020 under an Investigational New Drug application with the US Food and Drug Administration. NervGen is advancing NVG-291 for the treatment of spinal cord injury as the Company believes this indication is a significant opportunity due to the current lack of non-surgical solutions in the market, the dramatic impact on quality of life and the high cost burden to the healthcare system. The Company believes NVG-291 as a therapy could alleviate or improve upon the symptoms and conditions associated with spinal cord injury and empower these patients to live more active and productive lives.

About LD Micro

LD Micro was founded in 2006 with the sole purpose of being an independent resource in the microcap space.

What started out as a newsletter highlighting unique companies has transformed into several influential events annually (Invitational, Summit, and Main Event).

In 2015, LDM launched the first pure microcap index (the LDMi) to exclusively provide intraday information on the entire sector. LD will continue to provide valuable tools for the benefit of everyone in the small and micro-cap universe.

For those interested in attending, please contact David Scher at david@ldmicro.com or visit www.ldmicro.com for more information.

Contact:

Name: Bill Radvak
Email: bradvak@nervgen.com

Follow NervGen on Twitter (@NervgenC) and LinkedIn (NervGen Pharma Inc.) for the latest news on the Company.

SOURCE: NervGen Pharma Corp.

View source version on accesswire.com:
https://www.accesswire.com/547741/NervGen-Pharma-Corp-to-Present-at-the-9th-Annual-LD-Micro-Invitational

user

Recent Posts

Modular Medical Announces Pricing of $8.2 Million Public Offering

SAN DIEGO, CA / ACCESSWIRE / November 21, 2024 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular…

3 hours ago

Nicole Garrett and Under Pressure Hyperbarics Lead the Charge in Wellness Education With Immersive Events at L.A. Fashion Weekend and Beyond

BEVERLY HILLS, CALIFORNIA / ACCESSWIRE / November 21, 2024 / Nicole Garrett, CEO of Under…

6 hours ago

Beacon Healthcare Systems Expands Leadership Team with Addition of Ayman Mohamed as Chief Technology Officer

HUNTINGTON BEACH, Calif., Nov. 21, 2024 /PRNewswire/ -- Beacon Healthcare Systems, is pleased to announce…

8 hours ago

Talkiatry Ranked Number 6 Fastest-Growing Company in North America on the 2024 Deloitte Technology Fast 500™

Attributes Revenue Growth to Innovative Partnerships, Strong Team, and Unique Value-Based Care Model NEW YORK,…

8 hours ago

Bright Light Imaging Leverages Alpha Nodus’s Gravity Auth, Enhanced by Integration with ADS’s MedicsRIS, to Streamline Patient Care

Automation That Makes a Difference SUNRISE, Fla., Nov. 21, 2024 /PRNewswire/ -- When it comes…

8 hours ago